English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Diabetes treatment requires specialized multi-professional teams, supplies for blood glucose monitoring and training for self-injections of human insulin or insulin analogues. The State Health Secretariat of the Federal District (SHS-FD) has dispensed insulin analogues by means of clinical validated protocols since 2004. However, data on outcomes of follow-up are still unknown.    Objective  To evaluate the results of glycated hemoglobin (HbA1c) among diabetic patients treated with insulin analogues.    Methods  It is a retrospective cohort study involving data of type 1(DM1) and type 2 diabetes (DM2) patients 18 years old and above who were registered to participate at the insulin analogues dispense program of the SHS-FD. Evaluation of criteria of insulin treatment continuity was based on HbA1c values achieved in the follow-up period:  in the target , <7 %, patients between 18 and 65 years old; <8 % for those above 65 years old;  out of target , when values were superior these cut off points for both age groups; and  minimum 0.5   % reduction  of two HbA1c values during follow-up.    Results  Two hundred and fifteen formularies were analyzed: Type 2 patients (63.7 %) and female sex were the most prevalent (63.7 %), (p < 0.05). Mean age and SD were 41.5 ± 23.5 years among DM1 and 60.5 ± 28.5 in those with DM2. HbA1c  in the target  was found in 26 %, 48 % were  out of target  and 26 % achieved  0.5   % minimum reduction  in HbA1c value (p < 0.05). The main clinical characteristics associated with HbA1c found to be  in the target  were older age (>65 years), more than three medical appointments in the follow-up and lower mean HbA1c in the patient selection for inclusion criteria in the dispense program (p < 0.05).    Conclusion  The low number of patients using insulin analogues  in the target  group, considered to be in good control, implies the need to reevaluate both level of patients self-care knowledge and glucose monitoring prior their inclusion in the insulin analogue dispense program. Reinforcement and training of health professional teams in enrollment procedures should be on mandatory basis to avoid protocol failure or deviations.    Electronic supplementary material  The online version of this article (doi:10.1186/s13098-015-0061-0) contains supplementary material, which is available to authorized users.

Results of glycated hemoglobin during treatment with insulin analogues dispensed in the public health system of Federal District in Brazil